SCYNEXIS, Inc., founded in Durham, North Carolina, is a biotechnology company focused on discovering, developing, and distributing pharmaceutical products for the treatment of invasive fungal infections. The company's core mission is to address unmet medical needs in fungal infection treatments through innovative solutions. SCYNEXIS offers BREXAFEMME for vulvovaginal candidiasis (VVC) and recurrent VVC, and its lead product candidate, Ibrexafungerp, targets various severe fungal infections including invasive candidiasis and aspergillosis.
Notable affiliations include research collaborations with Merck Sharp & Dohme Corp. SCYNEXIS has achieved significant milestones, such as the FDA approval of BREXAFEMME, marking a new advancement in antifungal treatments. The company's impact is underscored by its commitment to providing effective therapies for challenging fungal infections, thereby improving patient outcomes and addressing critical gaps in the current treatment landscape.
